Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II canakinumab trial in Schnitzler syndrome
2010-024156-28Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Apr 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Schnitzler syndrome comparing Canakinumab with Placebo (2 arms). Primary endpoint: Complete response at day 7. Started Apr 2011; status: completed.
02
Drugs
canakinumab
03
Conditions
Schnitzler syndrome
Beyond the preview
Go deeper on 2010-024156-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024156-28.